{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pomalidomide&page=2", "query": { "intervention": "pomalidomide", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pomalidomide&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-07T11:47:00.513Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02963493", "title": "A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Melphalan flufenamide (Melflufen)", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncopeptides AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 157, "start_date": "2016-12-28", "completion_date": "2021-11-16", "has_results": true, "last_update_posted_date": "2022-11-22", "last_synced_at": "2026-06-07T11:47:00.513Z", "location_count": 9, "location_summary": "Whittier, California • Gainesville, Florida • Chicago, Illinois + 6 more", "locations": [ { "city": "Whittier", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02963493" }, { "nct_id": "NCT04150965", "title": "Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma", "Relapsed Refractory Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab, pomalidomide, dexamethasone", "type": "DRUG" }, { "name": "Anti-LAG-3", "type": "DRUG" }, { "name": "Anti-LAG-3 + Pomalidimide + Dexamethasone", "type": "DRUG" }, { "name": "Anti-TIGIT", "type": "DRUG" }, { "name": "Anti-TIGIT + Pomalidimide + Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Multiple Myeloma Research Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2020-07-10", "completion_date": "2024-08-30", "has_results": false, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-06-07T11:47:00.513Z", "location_count": 10, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan + 5 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04150965" }, { "nct_id": "NCT05455320", "title": "A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed or Refractory Multiple Myeloma" ], "interventions": [ { "name": "Talquetamab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 864, "start_date": "2022-10-13", "completion_date": "2028-05-25", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-06-07T11:47:00.513Z", "location_count": 40, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Norwalk, Connecticut + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05455320" }, { "nct_id": "NCT03170882", "title": "A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed and/or Refractory Multiple Myeloma" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2017-08-01", "completion_date": "2021-11-26", "has_results": true, "last_update_posted_date": "2022-12-20", "last_synced_at": "2026-06-07T11:47:00.513Z", "location_count": 10, "location_summary": "Fayetteville, Arkansas • Santa Rosa, California • Boca Raton, Florida + 7 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03170882" }, { "nct_id": "NCT02548962", "title": "Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 11, "start_date": "2016-03", "completion_date": "2018-06-13", "has_results": true, "last_update_posted_date": "2019-11-21", "last_synced_at": "2026-06-07T11:47:00.513Z", "location_count": 5, "location_summary": "Duarte, California • Boston, Massachusetts • Cleveland, Ohio + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02548962" }, { "nct_id": "NCT03713294", "title": "Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Elotuzumab", "type": "BIOLOGICAL" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2019-01-14", "completion_date": "2024-11-14", "has_results": true, "last_update_posted_date": "2025-06-24", "last_synced_at": "2026-06-07T11:47:00.513Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03713294" }, { "nct_id": "NCT02431208", "title": "A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2015-07-22", "completion_date": "2021-03-19", "has_results": false, "last_update_posted_date": "2021-04-02", "last_synced_at": "2026-06-07T11:47:00.513Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02431208" }, { "nct_id": "NCT01575925", "title": "Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Renal Impairment" ], "interventions": [ { "name": "4 mg Oral POM + 40 mg Oral DEX", "type": "DRUG" }, { "name": "2 mg Oral POM + 40 mg Oral DEX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2012-06-01", "completion_date": "2018-08-07", "has_results": false, "last_update_posted_date": "2022-11-04", "last_synced_at": "2026-06-07T11:47:00.513Z", "location_count": 7, "location_summary": "Denver, Colorado • Atlanta, Georgia • Harvey, Illinois + 4 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01575925" }, { "nct_id": "NCT05714839", "title": "A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Unconjugated belantamab antibody", "type": "DRUG" }, { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Unconjugated belantamab antibody and belantamab mafodotin", "type": "DRUG" }, { "name": "Unconjugated belantamab antibody in combination with pomalidomide-dexamethasone backbone, with or without belantamab mafodotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2023-06-14", "completion_date": "2029-12-03", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-07T11:47:00.513Z", "location_count": 4, "location_summary": "Grand Rapids, Michigan • Chapel Hill, North Carolina • Chattanooga, Tennessee + 1 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Chattanooga", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05714839" }, { "nct_id": "NCT07222761", "title": "A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed and/or Refractory Multiple Myeloma (RRMM)" ], "interventions": [ { "name": "Linvoseltamab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 915, "start_date": "2026-01-02", "completion_date": "2034-08-23", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-07T11:47:00.513Z", "location_count": 2, "location_summary": "New York, New York • Columbus, Ohio", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07222761" } ] }